Estradiol
Also known as: E2, estrogen
Medically reviewed by Hormone Journal Editorial Team · Last reviewed 2026-05-22
Estradiol (E2) is the most potent estrogen in the human body, dominating reproductive-age physiology and falling sharply at menopause to levels below 30 pmol/L.
What it is
Estradiol (E2) is the most potent and abundant estrogen in the human body during the reproductive years, with circulating levels ranging from roughly 70–1,750 pmol/L across the menstrual cycle and dropping to below 30 pmol/L after menopause. Also called 17β-estradiol, it is one of four naturally occurring estrogens — alongside estrone (E1), estriol (E3), and estetrol (E4) — and is the form measured in standard hormone panels ordered through Canadian labs such as LifeLabs and Dynacare.
Estradiol is produced primarily by the ovarian granulosa cells in people with ovaries, and in smaller amounts by the testes, adrenal glands, and peripheral tissues including adipose, bone, brain, and vascular endothelium. In postmenopausal women and transgender women receiving hormone therapy, peripheral conversion of androgens to estradiol in adipose tissue becomes the dominant source of endogenous E2.
The hormone acts through two nuclear receptors — estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) — which are expressed in virtually every organ system. This broad receptor distribution explains why estradiol influences not just reproductive function but also cardiovascular health, bone density, lipid metabolism, mood, cognition, and thermoregulation.
| Estrogen | Relative potency | Primary source | Clinical relevance |
|---|---|---|---|
| Estradiol (E2) | Highest | Ovaries (reproductive years) | Menopause therapy, fertility, HRT monitoring |
| Estrone (E1) | Moderate | Adipose (postmenopause) | Dominant postmenopausal estrogen |
| Estriol (E3) | Low | Placenta | Pregnancy marker; some vaginal formulations |
| Estetrol (E4) | Low–moderate | Fetal liver | Newer oral contraceptive component |
Causes and mechanism
During the menstrual cycle, the hypothalamic-pituitary-ovarian (HPO) axis drives estradiol synthesis. Gonadotropin-releasing hormone (GnRH) from the hypothalamus stimulates the pituitary to release follicle-stimulating hormone (FSH) and luteinizing hormone (LH), which in turn signal ovarian granulosa cells to convert androgens into estradiol via the enzyme aromatase. Estradiol peaks twice per cycle: a large surge just before ovulation (roughly 400–1,750 pmol/L) and a smaller luteal-phase rise.
When ovarian function declines — whether through natural menopause, surgical oophorectomy, primary ovarian insufficiency (POI), or gonadotropin-suppressing treatments — estradiol production falls sharply. The resulting estrogen deficiency drives the majority of menopausal symptoms and accelerates bone loss. In men and transgender women, estradiol is produced through peripheral aromatization of testosterone; low E2 in men is associated with reduced bone density and impaired spermatogenesis.
Symptoms and diagnosis
Low estradiol produces a recognizable cluster: vasomotor symptoms (hot flashes, night sweats), urogenital atrophy (vaginal dryness, dyspareunia, recurrent UTIs), disrupted sleep, mood changes, reduced libido, and accelerated bone loss. Cognitive symptoms — difficulty concentrating, memory lapses — are increasingly recognized as part of the estrogen-deficient state, though the mechanisms remain an active area of research.
Elevated estradiol can occur with ovarian tumours, obesity-related aromatase excess, or exogenous estrogen use, and may present as irregular bleeding, breast tenderness, or gynecomastia in men.
Diagnosis relies on serum E2 measurement. In Canada, this is a standard requisition available through most provincial health plans when ordered by a physician or nurse practitioner. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is the gold-standard method, particularly at low concentrations (postmenopausal or pediatric ranges), where immunoassays are prone to significant inaccuracy — a limitation formally recognized in an Endocrine Society position statement. Reference ranges vary by lab, cycle phase, and assay method, so results should always be interpreted alongside clinical context and the specific lab's reference intervals.
Treatment options
When estradiol deficiency is confirmed and treatment is indicated, the primary intervention is menopausal hormone therapy (MHT), also called hormone replacement therapy (HRT). Health Canada has approved multiple estradiol formulations:
- Transdermal patches and gels (e.g., Estradot, Estrogel) — bypass first-pass hepatic metabolism, associated with lower venous thromboembolism risk than oral forms
- Oral estradiol (e.g., Estrace) — convenient but subject to hepatic conversion to estrone
- Vaginal preparations (creams, rings, tablets) — for localized genitourinary symptoms with minimal systemic absorption
- Injectable estradiol — used in some gender-affirming hormone protocols
People with an intact uterus require concurrent progestogen to protect the endometrium. The Society of Obstetricians and Gynaecologists of Canada (SOGC) and The Menopause Society both support initiating MHT in symptomatic women under 60 or within 10 years of menopause onset, where benefits generally outweigh risks.
For Canadians exploring MHT, prescriptions can be obtained through a family physician, gynaecologist, or via virtual care platforms such as Felix, Cleo, Maple, Phoenix, or Science & Humans — allowing patients to compare services and access care regardless of geography.
When to see a clinician in Canada
Seek assessment if you experience: moderate-to-severe hot flashes or night sweats disrupting sleep or daily function; vaginal dryness causing pain with intercourse or recurrent infections; irregular or absent periods before age 45; bone fractures without significant trauma; or mood and cognitive changes coinciding with menstrual cycle changes. A serum E2 test, along with FSH and LH, is typically the first step and can be requisitioned by any primary care provider. Provincial coverage for the blood test varies; in most provinces it is covered under provincial health insurance when ordered for a clinical indication.
Limitations and open questions
Research is still emerging on several fronts. The "timing hypothesis" — that estradiol therapy is cardioprotective when started close to menopause but potentially neutral or harmful when started more than 10 years after — is supported by observational data but not fully resolved by randomized trials. The long-term cognitive effects of estradiol therapy, including any role in Alzheimer's risk reduction, remain contested; the 2024 Frontiers in Endocrinology literature review notes mechanistic plausibility but acknowledges that clinical trial evidence is inconsistent.
Assay accuracy at low estradiol concentrations is a recognized problem: the Endocrine Society's position statement (Rosner et al., JCEM 2013) found that many immunoassay platforms perform poorly below 70 pmol/L, which is precisely the postmenopausal range where clinical decisions are most consequential. Health Canada has not issued specific guidance on which assay method provincial labs must use for E2 measurement, meaning result interpretation can vary across provinces.
The optimal estradiol target range during MHT has not been established by randomized controlled trial evidence, and individualized dosing based on symptom response remains standard practice rather than a defined serum threshold.
FAQs
What is a normal estradiol level, and what do my results mean?
Normal estradiol levels vary widely depending on where you are in your menstrual cycle: roughly 70–530 pmol/L in the follicular phase, up to 1,750 pmol/L at the pre-ovulatory peak, and 30–440 pmol/L in the luteal phase. After menopause, levels typically fall below 30 pmol/L. Because reference ranges differ between labs and assay methods, your result should always be interpreted alongside your symptoms and the specific reference intervals provided by the lab that ran your test — LifeLabs and Dynacare, the two largest networks in Canada, each publish their own ranges.
How is estradiol different from estrogen?
Estrogen is the umbrella term for a class of hormones; estradiol (E2) is the specific estrogen that dominates during the reproductive years and is the most biologically potent of the four naturally occurring forms. The others — estrone (E1), estriol (E3), and estetrol (E4) — are either weaker, produced mainly during pregnancy, or relevant primarily in postmenopausal physiology. When clinicians order an 'estrogen' blood test, they are almost always measuring estradiol specifically.
Is estradiol therapy covered by provincial drug plans in Canada?
Coverage varies by province and formulation. In Ontario, several estradiol products (including Estrace tablets and Estradot patches) are listed on the Ontario Drug Benefit (ODB) formulary for eligible recipients. British Columbia's PharmaCare and Alberta's drug benefit program also cover select formulations, generally requiring a valid prescription for a listed indication such as menopausal symptoms or osteoporosis prevention. Patients should check their provincial formulary or ask their pharmacist, as coverage tiers and co-pay amounts differ. Private insurance plans typically cover a broader range of formulations.
Does estradiol therapy increase breast cancer risk?
The relationship between estradiol therapy and breast cancer risk is nuanced and depends on the type of hormone therapy used. Estradiol-only therapy (used in women without a uterus) is associated with little to no increase in breast cancer risk over 5–7 years of use, according to data from the Women's Health Initiative. The elevated risk seen in combined estrogen-progestogen therapy is largely attributed to the progestogen component, particularly synthetic progestins; micronized progesterone appears to carry lower risk than medroxyprogesterone acetate. The SOGC and The Menopause Society both advise that for most women under 60 who are within 10 years of menopause, the absolute risk increase is small and should be weighed against the benefits of symptom relief and bone protection.
Can men and transgender women have their estradiol tested and treated in Canada?
Yes. Estradiol testing is clinically relevant for men — low E2 in men is associated with bone loss and impaired fertility — and is a standard monitoring parameter in gender-affirming hormone therapy (GAHT) for transgender women. In Canada, GAHT is increasingly accessible through primary care, with informed-consent models available in several provinces. Virtual care platforms including Maple, Felix, and others can facilitate initial assessment and prescribing. Target estradiol ranges for transgender women on GAHT are generally 200–600 pmol/L, though protocols vary by provider and are individualized based on response and safety monitoring.
Sources
- Estradiol — StatPearls, NIH National Library of Medicine
- Challenges to the Measurement of Estradiol: An Endocrine Society Position Statement (Rosner et al., JCEM 2013)
- The impact of 17β-estradiol on the estrogen-deficient female brain (Frontiers in Endocrinology, 2024)
- Estradiol blood test — MedlinePlus Medical Encyclopedia, NIH
- Menopause: Vasomotor Symptoms, Hormonal and Non-Hormonal Treatments — SOGC Clinical Practice Guideline No. 422
- The 2023 Menopause Society Position Statement on Hormone Therapy